Coastar Therapeutics is a pre-clinical biotech company developing biological payload delivery technologies for cancer immunotherapy and gene therapies. Our proprietary ENHEnSTM technology can be used to coat biological payloads with cell membranes, which help them evade recognition and clearance by the immune system and be successfully delivered to tumor or other disease sites. We have four pipelines with our partners, and more are on the way.
Our Mission
Mr. Chung has extensive industry leadership experience managing projects from R&D to manufacturing, and led his team working on new pipeline technology transfer. He is also the board member of several companies. Mr. Chung received his MS degree in Bioengineering from UC San Diego and BS degree from National Tsinghua University.
A scientist and former executive of OncoFluidics (Sponsored by NSF), Dr. Lim has extensive experience on many interdisciplinary projects focusing on integrating synthetic or biological materials to engineer tissue from the micro- to macro-scale. Han has many peer-reviewed publications and was awarded funding from research grants to private investments. His works had attracted major pharma’s attention (Ex: Amgen). Dr. Lim received his PhD degree in Bioengineering from UC San Diego.
A scientist and seasoned business executive, Dr. Luo has profound experience in scientific R&D, product development, marketing, operations, and M&A. He has extensive startup experiences backed by leading Silicon Valley VC firms. Dr. Luo received his Ph.D. from UC Santa Barbara and his BS degree from Tsinghua University.
Dr. Glorioso is a pioneer of oncolytic virus and gene therapy. He founded the journal Nature Gene Therapy. He is a leading scientist on viral infection and mechanisms of antiviral immune responses. He has been a pioneer in the design and application of HSV gene vectors for the treatment of nervous system diseases such as peripheral neuropathies, chronic pain and brain tumors. Dr. Glorioso is a co-founder of Oncorus (NASDAQ: ONCR), an oncolytic virus company developing immunotherapy of cancer.
James Huang joined Kleiner Perkins China as a Managing Partner in 2011 and focused on the firm’s life sciences practice. Prior to KPCB he was a Managing Partner at Vivo Ventures and President of Anesiva. James has also held a number of senior positions across BD, marketing, and R&D functions with world leading healthcare companies, including Tularik Inc. (acquired by Amgen), GlaxoSmithKline LLC, Bristol-Meyers Squibb, and ALZA Corp. (acquired by Johnson & Johnson). James is Chairman of Board at Kindstar Global, Eden Biologics, ZioPharm Oncology and Director at GenScript, ChiralQuest, Zenesis, CVie Therapeutics, EntreMed, XW Laboratory, Omni Pharmaceuticals. James holds an M.B.A. from Stanford and a B.S. degree from UC Berkeley.
A leading scientist in cancer immunotherapy and gene therapy, Dr. Koya is a professor at the University of Chicago. He serves as peer-reviewer for various scientific journals in the field of cancer research and immunology, and is a grant reviewer in Scientific Review Study Sections of the National Institute of Health (NIH)/National Cancer Institute (NCI).
Dr. T. W. Chung has over 30 years of experience in biomaterial and drug delivery. He is a professor of biomedical engineering at National Yang Ming Chiao Tung University in Taiwan. His research focus in biomaterials, tissue engineering, regenerative medicine and drug delivery. He is a Fellow of the American Institute of Medical and Biological Engineering (AIMBE).